Urology & Urogynecology Archives - Laborie

Urology & Urogynecology

Laborie Announces First Procedures in ENDURE 1 Study with the Optilume® Ureteric Drug-Coated Balloon

Urology & Urogynecology

Laborie’s Optilume® Drug-Coated Balloon for Stricture Secures Coverage from BCBS of Michigan

Effective July 1, 2025, Blue Cross Blue Shield of Michigan (BCBSM) has issued a new medical policy under CPT code 52284, extending coverage for Laborie Medical Technologies’ Optilume® Urethral Drug-Coated Balloon for Stricture to eligible Commercial HMO members. This new coverage reinforces Laborie’s ongoing commitment to enhancing patient outcomes through wider access to evidence-based medical technologies.

Urology & Urogynecology

Three-Year Data from ROBUST III Confirms Long-Term Durability of Optilume® Drug-Coated Balloon for Recurrent Urethral Strictures

Laborie Medical Technologies Corp. (Laborie), a global leader in diagnostic and therapeutic urology, announced the publication of three-year outcomes from the ROBUST III randomized controlled trial in the Journal of Endourology. The results underscore the long-term durability and safety of the Optilume® Drug-Coated Balloon (DCB) as a minimally invasive treatment for recurrent anterior urethral strictures in men.

Urology & Urogynecology

Optilume Drug-Coated Balloon Shows Long-Term Efficacy for Urethral Strictures: Five-Year Data Published in the Journal of Urology

Urology & Urogynecology

Optilume® BPH Catheter System Issued Category 1 CPT Code by American Medical Association

Urology & Urogynecology

Laborie Unveils Positive Study Results for Optilume® BPH Catheter System

Laborie announced positive 2-year and 5-year results from studies for its Optilume® BPH Catheter System.

Urology & Urogynecology

NHS England Reimburses Optilume® Urethral Drug Coated Balloon as Part of the Specialised Services Device Programme

Laborie welcomed the inclusion of Optilume® Urethral Drug-Coated Balloon (DCB) into the National Health Service (NHS) Specialized Services Device Programme (SSDP) as of April 1, 2024.

Urology & Urogynecology

Laborie Medical Technologies Invests in iO Urology and the CarePath Uroflow Device

Laborie Medical Technologies  announced a strategic equity investment in Bright Uro, an early-stage medical technology company headquartered in Irvine, CA.

Urology & Urogynecology

Laborie Medical Technologies Acquires Urotronic

Urotronic joins Laborie as part of a long-term growth strategy for the Portsmouth-based medical device company. Urotronic’s Optilume® BPH Catheter System, a unique minimally invasive surgical therapy (MIST), is a paradigm shift for patients and clinicians in global interventional urology.

Urology & Urogynecology

Laborie Medical Technologies Announces Agreement to Acquire Urotronic for up to $600 Million

Acquisition expands urology portfolio and demonstrates Laborie’s commitment to providing proven, innovative solutions to physicians and patients globally

Page 1 of 312 3 »